By Colin Kellaher
Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company.
Stoke on Tuesday said Ian Smith, a board member since September 2023, will step in as interim CEO, adding that it has launched a search for a permanent replacement for Kaye.
The Bedford, Mass., company said its chairman, Arthur Tzianabos, will serve as interim executive chairman and lead the CEO search.
Stoke said Kaye, who joined the company as CEO and a director in October 2017, will continue to serve as an adviser and non-executive board member.
The company said Kaye, 75 years old, will be entitled to receive payment of his current annual salary of $680,214 for 12 months, and that his existing equity awards will continue to vest as long as he is providing services as a board member or as an adviser.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 18, 2025 07:22 ET (11:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。